ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer
Videos  >  

Diaz Discusses the FDA Approval of Pembrolizumab for MSI-H Solid Tumors

Luis A. Diaz Jr, MD
Published Online:1:13 PM, Mon July 10, 2017

Luis A. Diaz Jr., MD, head, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of pembrolizumab (Keytruda) for microsatellite instability-high (MSI-H) colorectal cancer and other tumor types.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.